1
1Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States
2Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, United States
3Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, United States
4Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, United States
Tumor-stromal interactions within the tumor microenvironment (TME) influence lung cancer progression and response to therapeutic interventions, yet traditional
in vitro studies fail to replicate the complexity of these interactions. Herein, we developed three-dimensional (3D) lung tumor models that mimic the human TME and demonstrate tumor-stromal crosstalk mediated by extracellular vesicles (EVs). EVs released by tumor cells, independent of p53 status, and fibroblasts within the TME mediate
New-york
United-states
Franklin-lakes
California
Fort-collins
Colorado
Westborough
Lebanon
San-diego
Fiji
South-korea
Denver
Published: Jan 14, 2021
LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE)
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has completed enrollment (n=45) in its pilot clinical study evaluating the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler (“pMDI”) formulation in U.S. patients hospitalized with COVID-19.
David Zaccardelli, Pharm. D., President and CEO of Verona Pharma, said: “Completing enrollment of the pilot study in COVID-19 is an important milestone and we are on track to report top-line results in the second quarter of 2021. We are pleased vaccines are now approved for the prevention of COVID-19; however, a significant unmet need remains for effective treatments for symptomatic patients. We believe ensifentrine, with its novel mechanism of action, could help to improve COVID-19 patient outcomes.”
London
City-of
United-kingdom
Kimberly-minarovich-michael-barron
David-zaccardelli
Verona-pharma
Strategic-communications
International-media
Nasdaq
University-of-alabama-at-birmingham
Lancet-respir-med
European-investor-enquiries